SCHEMBL8723879

SCHEMBL8723879

O=C(NCC(O)c1ccccc1)c1cccnc1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.72
RAB9A P51151 4/20 0.72
SMN1; SMN2 Q16637 3/20 0.72
EPHX2 P34913 4/20 0.67
CYP2C9 P11712 1/20 0.67
CYP2C19 P33261 1/20 0.67
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
THRB P10828 1/20 0.59
KDM4E B2RXH2 1/20 0.55
TAAR1 Q96RJ0 1/20 0.55
ALDH1A1 P00352 1/20 0.54
PLOD2 O00469 1/20 0.53
BCAT2 O15382 1/20 0.53
PRMT5 O14744 1/20 0.52
WDR77 Q9BQA1 1/20 0.52
HDAC1 Q13547 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3224949 0.85 NPC1 (1.00) NPC1RAB9ASMN1; SMN2EPHX2KMT2A
SCHEMBL13495002 0.85 NPC1 (1.00) NPC1RAB9ASMN1; SMN2EPHX2KMT2A
SCHEMBL21523088 0.84 EPHX2 (0.65) NPC1RAB9ASMN1; SMN2EPHX2CYP2C9
SCHEMBL21523087 0.84 EPHX2 (0.65) NPC1RAB9ASMN1; SMN2EPHX2CYP2C9
SCHEMBL1568754 0.84 RAB9A (0.79) NPC1RAB9ASMN1; SMN2EPHX2CYP2C9
SCHEMBL8482617 0.81 EPHX2 (0.64) NPC1RAB9ASMN1; SMN2EPHX2CYP2C9
SCHEMBL28115750 0.81 KMT2A (0.69) NPC1RAB9ASMN1; SMN2EPHX2CYP2C9
SCHEMBL8722504 0.81 KMT2A (0.69) NPC1RAB9ASMN1; SMN2EPHX2CYP2C9
SCHEMBL5947875 0.80 EPHX2 (1.00) NPC1RAB9ASMN1; SMN2EPHX2CYP2C9
SCHEMBL28309218 0.79 THRB (0.71) NPC1RAB9ASMN1; SMN2EPHX2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0335545-B2 Pharmaceutical formulations for parenteral use UNIV FLORIDA (US) 1998-09-23 EP disclosed
EP-0327766-B1 Redox systems for brain-targeted drug delivery UNIV FLORIDA (US) 1998-04-08 EP disclosed
US-5024998-A Administering in aqueous solution with cyclodextrin derivative UNIVERSITY OF FLORIDA (US) 1991-06-18 US disclosed
US-5017566-A Redox systems for brain-targeted drug delivery UNIVERSITY OF FLORIDA (US) 1991-05-21 US disclosed
US-5002935-A Inclusion Complexing Hydroxypropylcyclodextrin with a Dihydropyridine-substituted Drug UNIVERSITY OF FLORIDA (US) 1991-03-26 US disclosed
US-4983586-A Decreasing precipitation at injection site or in lungs or other organs by combining with hydroxypropyl-beta-cyclodextrin UNIVERSITY OF FLORIDA (US) 1991-01-08 US disclosed
EP-0335545-A2 Pharmaceutical formulations for parenteral use UNIVERSITY OF FLORIDA (US) 1989-10-04 EP disclosed
EP-0327766-A2 Redox systems for brain-targeted drug delivery UNIVERSITY OF FLORIDA (US) 1989-08-16 EP disclosed